Search the Newsreel

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Alnylam Pharmaceuticals has experienced a significant stock sell-off due to lowered revenue guidance for its ATTR products and competition from BridgeBio. However, the article argues that the market reaction is overdone, highlighting Amvuttra's strong sales growth, a favorable competitive landscape after a rival drug's …

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

Oppenheimer Asset Management Inc. Buys New Position in CSW Industrials, Inc. $CSW

Oppenheimer Asset Management Inc. has acquired a new position of 14,518 shares in CSW Industrials, Inc. (NYSE:CSW), valued at approximately $4.04 million. CSW Industrials recently reported strong quarterly earnings, beating analyst estimates with an EPS of $3.84 and a 33% year-over-year revenue increase. The …

AMAT Q2 Deep Dive: AI Demand and Advanced Packaging Drive Guidance Upside, Market Reacts Cautiously

AMAT Q2 Deep Dive: AI Demand and Advanced Packaging Drive Guidance Upside, Market Reacts Cautiously Semiconductor machinery manufacturer Applied Materials (NASDAQ:AMAT) announced better-than-expected revenue in Q2 CY2026, with sales up 24.8% year on year to $9.12 billion. On top of that, next quarter's revenue …

GSA Capital Partners LLP Purchases New Shares in Commercial Metals Company $CMC

GSA Capital Partners LLP has acquired a new stake of 33,406 shares in Commercial Metals Company (NYSE:CMC), valued at approximately $2.096 million. Other institutional investors have also adjusted their positions, and insider activity shows the CEO and a director purchasing shares. The company recently …

13,576 Shares in Eagle Materials Inc $EXP Bought by GSA Capital Partners LLP

GSA Capital Partners LLP recently acquired a new stake of 13,576 shares in Eagle Materials Inc (NYSE:EXP), valued at approximately $3.055 million, during the second quarter. Other institutional investors also adjusted their holdings in the company, with notable increases from EverSource Wealth Advisors LLC, …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Commonwealth Retirement Investments LLC Reduces Holdings in Applied Materials, Inc. $AMAT

Focus Partners Advisor Solutions LLC Acquires New Holdings in Wheaton Precious Metals Corp. $WPM

Focus Partners Advisor Solutions LLC has acquired 20,080 shares of Wheaton Precious Metals Corp. (NYSE:WPM) worth approximately $2.26 million. This move comes as other institutional investors have also adjusted their holdings in the company, which reported strong quarterly earnings with EPS exceeding estimates and …

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Assenagon Asset Management S.A. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 57,075 shares, decreasing its holdings by 73.1%. Despite this, other institutional investors have either increased their positions or acquired new ones in ACADIA Pharmaceuticals. Insider selling also occurred, with executives …

Eagle Materials Inc (NYSE:EXP) Given Average Rating of "Hold" by Brokerages

Eagle Materials Inc. (NYSE:EXP) has received an average "Hold" rating from ten brokerages, with nine analysts recommending a hold and one a buy. The average 12-month price target is $222.56, slightly above its current share price of $208.35. The company's recent quarterly earnings missed …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Applied Digital Corporation (NASDAQ:APLD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Applied Digital Corporation (NASDAQ:APLD) has received an average "Moderate Buy" recommendation from brokerages, with an average 12-month price target of $68.15. Despite a significant year-over-year revenue increase of 406.3%, the company missed EPS estimates, reporting a loss of $0.39 against an expected loss of …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Solstice Advanced Materials, Inc. (SOLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solstice Advanced Materials, Inc. (NASDAQ: SOLS) following a significant stock price drop after its announcement to acquire Element Solutions for $14.5 billion. Despite the CEO's positive outlook on the acquisition, …

Dorchester Minerals (DMLP) Could Be 74% Below Fair Value As Earnings Improve

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Number of shareholders of Nexmetals Mining Corp. Warrant 2025-17.11.2027 on Nexmetals mng – TSXV:NEXM.WT

This article provides details for Nexmetals Mining Corp. Warrant 2025-17.11.2027, traded on the TSX Venture Exchange under the symbol NEXM.WT. It includes information on the number of shareholders and financial data, indicating that the market is currently closed with no trades. The content appears …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug

Madrigal Pharmaceuticals (MDGL) is attracting retail investor attention due to newly acquired U.S. patents for its lead liver disease drug, Rezdiffra, and ongoing speculation about a potential acquisition, possibly by Eli Lilly. Rezdiffra is Madrigal's sole marketed product, and the company is actively expanding …

Shoals Technologies Group (SHLS) Is Down 5.4% After Reaffirming 2026 Outlook And Storage Partnership News

New Pacific Metals (TSX:NUAG) Files Carangas Report, Is The Premium Already Priced In?

ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC

SEALSQ Updates Post-Quantum Chip Certification Schedule, Targets QVault Revenue by End-2026

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …

Osisko Metals - OM - Stock Price & News

Applied Industrial Technologies To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday

This article compiles the latest analyst ratings and price target adjustments for ten different companies, including Applied Industrial Technologies, Eton Pharmaceuticals, Pelagos Insurance Capital, Braze, Veritone, Powell Industries, Applied Materials, Yeti Holdings, Workday, and Intuitive Machines. Analysts from firms like Mizuho, HC Wainwright & …

Nexmetals Mining Corp. Warrant 2025-17.11.2027 on Nexmetals mng

This page provides financial information for Nexmetals Mining Corp. Warrant 2025-17.11.2027 (TSXV:NEXM.WT), focusing on its enterprise value to revenue forward. It indicates that the market was closed with no trades recorded at the time of publication. The data is sourced from ICE Data Services …

Modi Naturals Publishes Q1 FY2026 Unaudited Results in Newspapers